VIVOS INC

RDGL
About the company

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.

Country: United StatesPrice: $0.04Market Cap: $22.6M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2830 (Top 91.4%)FAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 2✗ 26▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio12.1x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-15.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.0%, ROC=-4085.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share12.1x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-9.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=12.1x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.04)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-16.92%; #4459/6340 (top 70.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.0912; #4793/6449 (top 74.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share12.07x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+3284.5%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0056; #4915/5247 (top 93.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-9.56%; #3215/4519 (top 71.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-45.68%; #5009/6202 (top 80.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-3.3M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-2.2M
      ✗LynchPositive and growing
      Operating Cash Flow$-2.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-110.18%, ROA=-164.17%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-9.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/4 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-10.8%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/16 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-2.2M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-9.56%; #3215/4519 (top 71.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Verdicts0% pass✗ 15▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2830✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag RDGL's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/20 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/20 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-170.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-4628.7% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-3.3M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-185.4%
      ✗Lynch> 15%
      EBIT / Enterprise Value-15.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.0%, ROC=-4085.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-164.17%
      ✗PiotroskiROA > 0
      ROA Change YoY-130.31% -> -164.17% (delta: -33.86%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-110.18%, ROA=-164.17%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY-4.0% -> -87.4%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-3032.9%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-185.4%
      ✗Dreman> 12%
      Margin of SafetyP/B=12.1x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-177.4% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-2414.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-185.4%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-14323.8% (2023) -> -4628.7% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin -31.0% -> -87.4%, operating margin -14323.8% -> -4628.7%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-16.92%; #4459/6340 (top 70.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+0.38%; #3409/3702 (top 92.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-185.44%; #4848/5226 (top 92.8%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1721; #4067/5884 (top 69.1%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag RDGL's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities12.33
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Growth13% pass✓ 3✗ 10▾

      7 of 8 flag RDGL's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -10.7% vs Rev: 159.4%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.06 (2014) -> $-0.01 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-8.8%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency0/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin -31.0% -> -87.4%, operating margin -14323.8% -> -4628.7%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR57.7%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag RDGL's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio12.33
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-4085.9%
      ✗Greenblatt> 25%
      Current Ratio Change YoY25.91 -> 14.00
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.03x -> 0.04x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities12.33
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($22.6M)
    Revenue: $68379.00-8.8% YoY
    Net Income: $3.1M-5.3% YoY

    Financial Snapshot

    Operating Margin-4628.7%
    Return on Equity-184.6%
    Debt / Equity--
    Current Ratio14.00
    EPS (Diluted)$-0.01
    Shares Retired−3.3% / −16.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 3.3% of shares last year, 16.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-24
    FY 2023
    Sources
    • 10-K · 2024-03-18
    FY 2022
    Sources
    • 10-K · 2024-03-18
    FY 2021
    Sources
    • 10-K · 2022-03-07
    Market Cap$22.6Mcurrent------$31.0Mest.$52.5Mest.$22.7Mest.$21.1Mest.$23.6Mest.
    Revenue$126.1K↑159%$28.9K↑1438%$36.4K↑143%$36.1K↑35%$68.4K↓9%$74.9K↑284%$19.5K↓47%$36.5K↑145%$14.9K
    Operating Income-$3.0M↓11%-$748.8K↓41%-$654.5K↑3%-$545.5K↑37%-$3.2M↓22%-$2.6M↑7%-$2.8M↓11%-$2.5M↓1%-$2.5M
    Net Income-$3.8M↓27%-$731.6K↓44%-$830.2K↓29%-$1.2M↓42%-$3.1M↓5%-$2.9M↓1%-$2.9M↓17%-$2.5M↑2%-$2.5M
    EPS (Diluted)--$0.00$0.00$0.00$-0.01$-0.01$-0.01$-0.01$-0.01
    Gross Margin6.8%↑105%74.3%↑111%-4.7%↑98%-22.2%↑35%-87.4%↓2095%-4.0%↑87%-31.0%↓246%21.2%↑9%19.4%
    Operating Margin-2414.0%↑57%-2591.1%↑91%-1798.2%↑60%-1512.4%↑53%-4628.7%↓33%-3475.5%↑76%-14323.8%↓108%-6898.1%↑59%-16805.3%
    ROE-185.4%↓34%———-184.6%↓36%-135.5%↑36%-212.1%↓43%-148.7%↑14%-172.3%
    Total Debt------------------
    Shareholders' Equity$2.1M↓5%$2.1M↓5%$2.8M↑3%$2.7M↓15%$1.7M↓23%$2.1M↑57%$1.4M↓18%$1.7M↑13%$1.5M
    Current Ratio12.33↓39%12.33↓39%48.85↑70%15.14↓47%14.00↓46%25.91↑294%6.57↓69%21.33↑118%9.79
    Debt / Equity—————————
    Operating Cash Flow-$2.3M↓16%-$593.4K↓29%-$739.6K↓22%-$429.9K↑6%-$2.1M↓22%-$1.7M↓30%-$1.3M↓15%-$1.1M↓16%-$963.8K
    Free Cash Flow-----$834.1K-$581.1K-$2.2M--------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    RDGL vs Peers — Financial Grading

    Revenue$68379.00Bottom 25%
    Net Income$3.1MBottom 25%
    ROE-184.6%Bottom 25%
    D/E—
    Op. Margin-4628.7%Bottom 25%
    Curr. Ratio14.00Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11